Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    126
    ...
ATC Name B/G Ingredients Dosage Form Price
G03DB08 VISANNE B Dienogest - 2mg 2mg Tablet 4,980,280 L.L
M05BB03 FOSAVANCE B Alendronic acid (sodium alendronate) - 70mg, Colecalciferol - 5600IU Tablet 1,988,887 L.L
A10BD07 JANUMET XR B Metformin HCl - 1,000mg, Sitagliptin - 50mg Tablet 4,777,360 L.L
G03DB08 DIENOSIS G Dienogest - 2mg 2mg Tablet 2,822,069 L.L
J05AF10 APO-ENTECAVIR G Entecavir - 0.5mg 0.5mg Tablet 28,943,287 L.L
M01AB05 REMETHAN G Diclofenac sodium - 50mg 50mg Tablet 196,201 L.L
M05BB03 ACIDE ALENDRONIQUE/ VITAMINE D3 BGR G Alendronic acid - 70mg, Colecalciferol - 5600UI Tablet 815,712 L.L
A10BD07 JANUMET XR B Metformin HCl - 1,000mg, Sitagliptin - 100mg Tablet 4,777,360 L.L
G03DC02 PRIMOLUT NOR B Norethisterone acetate - 5mg 5mg Tablet 296,989 L.L
G03FB01 PROGYLUTON B Norgestrel - 0.5mg (tablet 2), Estradiol valerate - 2mg (tablet 1, tablet 2) Tablet 193,513 L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg 10mg Tablet 12,966,030 L.L
R05FB02 MUCUS RELIEF DM G Dextromethorphan HBr - 20mg, Guaifenesin - 400mg Tablet 413,903 L.L
L01XX52 VENCLEXTA B Venetoclax - 50mg 50mg Tablet 31,367,183 L.L
L01XX52 VENCLEXTA B Venetoclax - 100mg 100mg Tablet 707,858,935 L.L
V03AC03 DEFERASIROX ARROW G Deferasirox - 90mg 90mg Tablet 8,846,092 L.L
J05AG01 NEPINE G Nevirapine - 200mg 200mg Tablet 5,921,678 L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg week 1, Venetoclax - 50mg week 2, Venetoclax - 100mg week 3&4 Tablet 190,943,809 L.L
P01AB01 METROLAG G Metronidazole - 500mg 500mg Tablet 389,714 L.L
P01AB01 RAMAZOL G Metronidazole - 500mg 500mg Tablet 216,359 L.L
C09AA01 ORBACE G Captopril - 25mg 25mg Tablet 522,179 L.L
C10AA01 ZOCOR B Simvastatin - 10mg 10mg Tablet 881,817 L.L
V03AC03 DEFERASIROX ARROW G Deferasirox - 180mg 180mg Tablet 13,280,846 L.L
P01AB01 METROLAG G Metronidazole - 250mg 250mg Tablet 130,353 L.L
C10AA01 STAVINE G Simvastatin - 10mg 10mg Tablet 207,336 L.L
P01AB01 METRONIDAZOLE G Metronidazole - 250mg 250mg Tablet 6,540,034 L.L
C09AA01 ORBACE G Captopril - 50mg 50mg Tablet 949,649 L.L
J01EE01 BACTRIM FORTE B Trimethoprim - 160mg, Sulfamethoxazole - 800mg Tablet 344,024 L.L
P01AB01 METRONIDAZOLE 250 G Metronidazole - 250mg 250mg Tablet 131,825 L.L
V03AC03 DEFERASIROX ARROW G Deferasirox - 360mg 360mg Tablet 18,379,327 L.L
C09AA02 RENITEC B Enalapril maleate - 20mg 20mg Tablet 405,840 L.L
    ...
    126
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025